PPARγ-induced stimulation of amiloride-sensitive sodium current in renal collecting duct principal cells is serum and insulin dependent

Cellular Physiology and Biochemistry

Volumn 33, Issue 3, 2014, Pages 581-593

  Chraïbi, Ahmed ^a   Renauld, Stéphane ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

ENaC; Nedd4; PPAR ; Rosiglitazone; SGK1

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMILORIDE; EPITHELIAL SODIUM CHANNEL; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; UBIQUITIN PROTEIN LIGASE NEDD4; DEXAMETHASONE; SODIUM CHANNEL; ACID SENSING ION CHANNEL; ESCRT PROTEIN; IMMEDIATE EARLY PROTEIN; NEDD4 UBIQUITIN PROTEIN LIGASES; PROTEIN SERINE THREONINE KINASE; SERUM-GLUCOCORTICOID REGULATED KINASE; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; KIDNEY COLLECTING TUBULE; KIDNEY TUBULE ABSORPTION; MOUSE; NEPHRON; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SODIUM ABSORPTION; SODIUM CURRENT; UBIQUITINATION; ENZYME ACTIVATION; INSULIN BLOOD LEVEL; KIDNEY CELL; SIGNAL TRANSDUCTION; SODIUM TRANSPORT; AGONISTS; ANIMAL; DRUG EFFECTS; METABOLISM; SERUM; TRANSFORMED CELL LINE;

ANIMALIA;

ACID SENSING ION CHANNELS; ANIMALS; CELL LINE, TRANSFORMED; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; EPITHELIAL SODIUM CHANNELS; IMMEDIATE-EARLY PROTEINS; INSULIN; KIDNEY TUBULES, COLLECTING; MICE; PPAR GAMMA; PROTEIN-SERINE-THREONINE KINASES; SERUM; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; UBIQUITIN-PROTEIN LIGASES;

EID: 84895659776     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358636     Document Type: Article

References (51)

1. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM: 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83:803-812.
2. Fuchtenbusch M, Standl E, Schatz H: Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000;108:151-163.
3. Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001;70:341-367.
4. Mudaliar S, Chang AR, Henry RR: Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003;9:406-416.
5. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108:2941-2948.
6. Niemeyer NV, Janney LM: Thiazolidinedione-induced edema. Pharmacotherapy 2002;22:924-929.
7. Thomas ML, Lloyd SJ: Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 2001;35:123-124.
8. Vasudevan AR, Balasubramanyam A: Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004;6:850-863.
9. Hauner H: The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002;18:S10-15.
10. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J: The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997;272:18779-18789.
11. Guan Y, Zhang Y, Davis L, Breyer MD: Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997;273:F1013-1022.
12. Hong G, Lockhart A, Davis B, Rahmoune H, Baker S, Ye L, Thompson P, Shou Y, O'Shaughnessy K, Ronco P, Brown J: PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. Faseb J 2003;17:1966-1968.
13. rd , Schnermann JB, Briggs JP: Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999;277:F966-973.
14. Zacchia M, Trepiccione F, Morelli F, Pani A, Capasso G: Nephrotic syndrome: new concepts in the pathophysiology of sodium retention. J Nephrol 2008;21:836-842.
15. + channel is made of three homologous subunits. Nature 1994;367:463-467.
16. Bhalla V, Hallows KR: Mechanisms of ENaC regulation and clinical implications. J Am Soc Nephrol 2008;19:1845-1854.
17. Inoue T, Nonoguchi H, Tomita K: Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. Cardiovasc Res 2001;51:470-480.
18. Son EJ, Kim SH, Park HY, Kim SJ, Yoon JH, Chung HP, Choi JY: Activation of epithelial sodium channel in human middle ear epithelial cells by dexamethasone. Eur J Pharmacol 2009;602:383-387.
19. Saad S, Agapiou DJ, Chen XM, Stevens V, Pollock CA: The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells. Nephrol Dial Transplant 2009;24:1130-1141.
20. + channel cell surface expression. Embo J 2001;20:7052-7059.
21. Soundararajan R, Zhang TT, Wang J, Vandewalle A, Pearce D: A novel role for glucocorticoid-induced leucine zipper protein in epithelial sodium channel-mediated sodium transport. J Biol Chem 2005;280:39970-39981.
22. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-866.
23. Beltowski J, Rachanczyk J, Wlodarczyk M: Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms. PPAR Res 2013;2013:628628.
24. Artunc F, Sandulache D, Nasir O, Boini KM, Friedrich B, Beier N, Dicks E, Potzsch S, Klingel K, Amann K, Blazer-Yost BL, Scholz W, Risler T, Kuhl D, Lang F: Lack of the serum and glucocorticoid-inducible kinase SGK1 attenuates the volume retention after treatment with the PPARgamma agonist pioglitazone. Pflugers Arch 2008;456:425-436.
25. Tiwari S, Blasi ER, Heyen JR, McHarg AD, Ecelbarger CM: Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats. Pharmacol Res 2008;57:383-392.
26. Renauld S, Tremblay K, Ait-Benichou S, Simoneau-Roy M, Garneau H, Staub O, Chraibi A: Stimulation of ENaC activity by rosiglitazone is PPARgamma-dependent and correlates with SGK1 expression increase. J Membr Biol 2010;236:259-270.
27. Chen L, Yang B, McNulty JA, Clifton LG, Binz JG, Grimes AM, Strum JC, Harrington WW, Chen Z, Balon TW, Stimpson SA, Brown KK: GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J Pharmacol Exp Ther 2005;312:718-725.
28. Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J, Dechenes G, Rossier B, Cunard R, Stockand J: Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity. J Am Soc Nephrol 2009;20:721-729.
29. + channel. Pflugers Arch 2005;451:445-453.
30. Napoli JL: Quantification of physiological levels of retinoic acid. Methods Enzymol 1986;123:112-124.
31. Abramoff MD, Magelhaes PJ, Ram SJ: Image Processing with Image J. Biophotonics International 2004;11:36-42.
32. Caohuy H, Jozwik C, Pollard HB: Rescue of DeltaF508-CFTR by the SGK1/Nedd4-2 signaling pathway. J Biol Chem 2009;284:25241-25253.
33. + channel. Mol Pharmacol 2009;76:1333-1340.
34. Blazer-Yost BL, Liu X, Helman SI: Hormonal regulation of ENaCs: insulin and aldosterone. Am J Physiol 1998;274:C1373-1379.
35. + channel density of apical membrane of cultured toad kidney cells. J Physiol 1994;481:533-542.
36. Shimamoto K, Hirata A, Fukuoka M, Higashiura K, Miyazaki Y, Shiiki M, Masuda A, Nakagawa M, Iimura O: Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension 1994;23:I29-33.
37. Garty H, Palmer LG: Epithelial sodium channels: function, structure, and regulation. Physiol Rev 1997;77:359-396.
38. Marunaka Y, Hagiwara N, Tohda H: Insulin activates single amiloride-blockable Na channels in a distal nephron cell line (A6). Am J Physiol 1992;263:F392-400.
39. Ruan X, Zheng F, Guan Y: PPARs and the kidney in metabolic syndrome. Am J Physiol Renal Physiol 2008;294:F1032-1047.
40. Tontonoz P, Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77:289-312.
41. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T: Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci US A2005;102:9406-9411.
42. Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA: Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004;308:426-433.
43. Yoshioka K, Wakino S, Homma K, Kanda T, Tatematsu S, Hasegawa K, Sugano N, Ito O, Omata K, Saruta T, Hayashi K: Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats. Obesity (Silver Spring) 2008;16:965-971.
44. Borsting E, Cheng VP, Glass CK, Vallon V, Cunard R: Peroxisome proliferator-activated receptor-gamma agonists repress epithelial sodium channel expression in the kidney. Am J Physiol Renal Physiol 2011;302:F540-551.
45. Monden T, Yamada M, Nihei Y, Kishi M, Tomaru T, Ishii S, Hashida T, Shibusawa N, Hashimoto K, Satoh T, Kasai K, Mori M: Unliganded RXR acts as an inhibitory factor on troglitazone-induced activation. Life Sci 2004;76:731-741.
46. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS: Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem 1997;272:20230-20235.
47. Kim SP, Ha JM, Yun SJ, Kim EK, Chung SW, Hong KW, Kim CD, Bae SS: Transcriptional activation of peroxisome proliferator-activated receptor-gamma requires activation of both protein kinase A and Akt during adipocyte differentiation. Biochem Biophys Res Commun 2010;399:55-59.
48. Yin Y, Yuan H, Wang C, Pattabiraman N, Rao M, Pestell RG, Glazer RI: 3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation. Mol Endocrinol 2006;20:268-278.
49. Bens M, Chassin C, Vandewalle A: Regulation of NaCl transport in the renal collecting duct: lessons from cultured cells. Pflugers Arch 2006;453:133-146.
50. + channels by aldosterone: role of Sgk1. Clin Exp Pharmacol Physiol 2008;35:235-241.
51. + channel. J Biol Chem 2002;277:5-8.